Therefore, anti-TIF1-γ antibodies, VEGF-A, TNF-α, CCL2, IL6, and IFN-γ could have essential roles in indicating the presence of cancer in anti-TIF1-γ antibody-positive DM patients (Figure 4A). This evidence concerns the gene TRIM33 and dermatomyositis.